olomoucine

Olomoucine is a synthetic purine derivative and small molecule that functions as an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs), particularly CDK1, CDK2, and CDK5. It acts by binding to the ATP-binding site of these kinases, thereby inhibiting their activity and disrupting cell cycle progression. Olomoucine preferentially induces cell death in cancer cell lines but can also affect non-cancer cells at higher concentrations or with prolonged exposure. Its primary research applications are in studying cell cycle regulation, anti-mitotic mechanisms, and potential anticancer effects. It has not been approved for clinical use in humans but is widely used as a tool compound in preclinical research[1][3][5][8].

Other names

6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine2-((6-(Benzylamino)-9-methyl-9H-purin-2-yl)amino)ethanolOlomucine